26.50
0.32 (1.22%)
| Previous Close | 26.18 |
| Open | 25.99 |
| Volume | 699,617 |
| Avg. Volume (3M) | 1,387,931 |
| Market Cap | 2,019,970,304 |
| Price / Sales | 2.84 |
| Price / Book | 2.91 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | CG Oncology, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (HC Wainwright & Co., 183.02%) | Buy |
| 75.00 (Cantor Fitzgerald, 183.02%) | Buy | |
| Median | 62.00 (133.96%) | |
| Low | 23.00 (Scotiabank, -13.21%) | Hold |
| Average | 56.33 (112.57%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 26.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 17 Jun 2025 | 56.00 (111.32%) | Buy | 26.50 |
| 19 May 2025 | 52.00 (96.23%) | Buy | 24.86 | |
| JP Morgan | 02 May 2025 | 41.00 (54.72%) | Buy | 29.05 |
| RBC Capital | 29 Apr 2025 | 68.00 (156.60%) | Buy | 26.94 |
| Cantor Fitzgerald | 28 Apr 2025 | 75.00 (183.02%) | Buy | 27.97 |
| HC Wainwright & Co. | 28 Apr 2025 | 75.00 (183.02%) | Buy | 27.97 |
| 31 Mar 2025 | 75.00 (183.02%) | Buy | 24.49 | |
| Scotiabank | 16 Apr 2025 | 23.00 (-13.21%) | Hold | 20.22 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |